이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

KalVista Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

KalVista Pharmaceuticals 의 총 주주 지분은 $206.6M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $235.4M 및 $28.8M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$174.27m
주식	US$172.80m
총 부채	US$27.40m
총 자산	US$200.20m

최근 재무 상태 업데이트

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18

Recent updates

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Sep 05

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24

We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

Jul 02

KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study

Jun 07

재무 상태 분석

단기부채: KALV 의 단기 자산 ( $225.7M )이 단기 부채( $22.8M ).

장기 부채: KALV 의 단기 자산( $225.7M )이 장기 부채( $6.0M ).

부채 대 자본 내역 및 분석

부채 수준: KALV 부채가 없습니다.

부채 감소: KALV 지난 5년간 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: KALV 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: KALV 25.9 1 25.9 % 매년.

KalVista Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

Recent updates

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Kalvista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024

KalVista Pharmaceuticals, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology (Eaaci) Congress 2024

Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

CEO & Director exercised options and sold US$258k worth of stock

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

New minor risk - Share price stability

CEO & Director exercised options and sold US$351k worth of stock

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

New minor risk - Shareholder dilution

CEO & Director recently sold US$876k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

KalVista Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $160.125 million.

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

New major risk - Financial position

CEO & Director exercised options and sold US$122k worth of stock

Price target increased by 7.6% to US$20.80

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Independent Director notifies of intention to sell stock

CEO & Director exercised options and sold US$160k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Consensus revenue estimates fall by 58%

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

CEO & Director exercised options and sold US$57k worth of stock

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

Price target decreased to US$21.83

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista: Another Setback But The Key Value Driver Is Still In Place

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Price target decreased to US$32.83

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

CEO & Director notifies of intention to sell stock

KalVista Pharmaceticals GAAP EPS of -$0.94

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

KalVista reaches five-month high as rival tumbles on hereditary angioedema

No longer forecast to breakeven

KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11

Price target decreased to US$41.67

KalVista Pharmaceuticals, Inc. Announces Board Changes